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HEPATITIS C VIRAL LOAD DOES NOT PREDICT DISEASE OUTCOME: GOING BEYOND NUMBERS
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SUMMARY
The analysis of 58 patients with chronic hepatitis C without cirrhosis and treated with interferon-alpha demonstrated that hepatitis
C viral (HCV) load does not correlate with the histological evolution of the disease (p = 0.6559 for architectural alterations and p =
0.6271 for the histological activity index). Therefore, the use of viral RNA quantification as an evolutive predictor or determinant of
the severity of hepatitis C is incorrect and of relative value. A review of the literature provided fundamental and interdependent HCV
(genotype, heterogeneity and mutants, specific proteins), host (sex, age, weight, etc) and treatment variables (dosage, time of treatment,
type of interferon) within the broader context of viral kinetics, interferon-mediated immunological response (in addition to natural
immunity against HCV) and the role of interferon as a modulator of fibrogenesis. Therefore, viral load implies much more than
numbers and the correct interpretation of these data should consider a broader context depending on multiple factors that are more
complex than the simple value obtained upon quantification.
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INTRODUCTION
Hepatitis C is the major cause of liver transplantation and cirrhosis
worldwide, affecting approximately 170 million people14, or two percent
of the global population, with regional variations being observed. Due
to its asymptomatic pathology even during advanced phases of the
disease, such as compensated cirrhosis, the diagnosis of hepatitis C is
completely based on laboratory exams. Therefore, most patients discover
their condition by chance during blood donations or routine examinations.
Antibodies are routinely detected by ELISA and hepatitis C virus (HCV)
infection is confirmed by the determination of viral RNA in blood using
the polymerase chain reaction (PCR) and staging by anatomopathological
examination of the liver.
In addition to the diagnosis, the HCV subtype and the amount of
virus in plasma need to be established since the present consensus therapy
varies according to these parameters7. After the diagnosis of chronic
hepatitis C and staging, patients presenting inflammatory activity and
structural alterations exceeding the portal area are indicated for the use
of interferon-alpha combined with ribavirin for a period of six to 12
months, a treatment scheme that leads to a sustained virological response
in 30 to 40% of cases30. Based on these data a series of questions should
be raised: what is the benefit of treatment for most non-responders?
What are the factors determining the presence or absence of a virological
response? Does HCV play a direct role in disease pathogenesis (with
the assumption that the higher its plasma concentration the poorer the
evolutive prognosis of the patient)?
Based on these still not completely understood aspects and the
massive use of costly HCV RNA quantification methods of limited
diagnostic value, such as the method used to confirm the diagnosis of
HCV infection, the aims of the present study were to establish the role
of the amount of HCV with respect to histological evolution and to
determine the factors correlated with a good course and a good therapeutic
response.
 MATERIAL AND METHODS
Fifty-eight patients with chronic hepatitis C confirmed by liver biopsy
and detection of viral RNA in serum by nested PCR were followed up at
the Hepatitis Outpatient Clinic, Department of Infectious and Parasitic
Diseases, Faculty of Medicine, University of São Paulo (DMIP/FMUSP),
from 1997 to 1998. The patients did not present decompensated co-
morbidities, other causes of chronic liver disease, cirrhosis, or HIV infection
and had not used alcohol or illegal drugs for six months before inclusion
in the study. Prior to inclusion written informed consent was obtained
from the patients or responsible persons and the study was approved by
the Ethics Committee of DMIP/FMUSP. Demographic and
epidemiological information was obtained and clinical follow-up consisted
of monthly visits and examinations until the end of treatment, followed
by quarterly visits, according to the care routine of the unit. The patients
received 3 x 106 IU interferon-alpha subcutaneously three times per week
for 12 months, according to the current consensus established by the
National Institutes of Health (NIH)22, irrespective of the therapeutic
response, except in the case of adverse effects or intolerance.
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Blood samples were collected before and 6 and 12 months after
treatment, processed within 2 h and aliquots were stored at –20 oC without
unnecessary thawing, as described by DAVIS et al.6, for qualitative PCR
(nested PCR performed in-house) and, if positive, for quantification
(AMPLICOR HCV MONITOR, ROCHE). In addition, the virus was
serotyped using commercially available techniques (ABBOTT - MUREX
HCV 1-6 Assay) according to manufacturer instructions. Liver biopsies
were obtained with a needle by the percutaneous route and analyzed by
a single, experienced pathologist who was unaware of the clinical data
and of the time of puncture (before or after treatment). The samples
were analyzed using the classification of ISHAK et al.15. A second biopsy
was obtained 180 days after the end of treatment.
The qualitative variables were submitted to the chi-square test or to
the Fisher exact test when the basic assumptions of the chi-square test
were not satisfying. The response probability was analyzed by stepwise
logistic regression. The following variables were compared with the
histological, virological and biochemical results: age (less or more than
40 years), sex (female as the favorable variable), means of diagnosis
(analysis versus donation), basal viral load and load after six months of
treatment (less versus more than 500,000 copies/ml), serotype (non-1
and 1), pretreatment histological activity index - HAI (lower or higher
than 3), pretreatment fibrosis (0 -1 versus higher than 2), and a history
of transfusion of blood or blood derivatives. The first two options were
considered the favorable ones.
 RESULTS
Table 1 shows the basic characteristics of the present series. A
predominance of male patients with a mean age of 40 years was observed.
Most of the patients acquired the infection through the transfusion of blood
and blood derivatives or through drug use. However, one third of the cases
did not report any suspected epidemiology. The diagnosis was mainly
made upon blood donations. Serotype 1 was the most common HCV
subtype (30 cases, one being co-infected with serotype 4), although 34%
of the patients were non-1 (4 were type 2 and 16 type 3). In most cases,
the viral load was below 500,000 copies/ml. There was a predominance
of patients with elevated HAI and slight structural alterations. Table 2
summarizes the results obtained after the beginning of therapy. Median
viral load decreased during the first six months of treatment, but this
reduction did not persist to the end of treatment. A virological response
was obtained in 21 cases and was sustained in 10 (17.2%). A biochemical
response was obtained in 19 cases and was sustained in 9 (15.5%).
Histological analysis revealed a reduction in inflammatory activity and
maintenance of the favorable architectural profile. Despite the slow
regression of the histological damage, a decrease in liver fibrosis of up to
two points was noted in three non-responders, i.e., histological
improvement dissociated from the virological response. In six cases, all
of them non-responders, a second biopsy could not be obtained.
Table 1
Basic characteristics of the series
Results n (%)
Gender Men 39 (67.2%)
Women   19 (32.8%)
Mean age 41 ± 9 years -
Epidemiology Transfusion 19 (32.8%)
Unknown 19 (32.8%)
Drugs 10 (17.2%)
Tattoos 2 (3.4%)
Infected relative 1 (1.7%)
Professional 2 (3.4%)
Multiple 5 (8.5%)
Diagnosis Donation 43 (74.1%)
Investigation 15 (25.9%)
Serotype 1 30 (one case
types 1 and 4)
51.7% (1.7%)
Non-1 20 (4 type 2;
16 type 3)
34.5%
Not obtained 8 (13.8%)
Viral load Median 43085.5 copies/ml
<500,000 copies/ml 51 (87.9%)
>500,000 copies/ml 7 (12.1%)
Liver Architecture 0-1 43 (74.1%)
2-3 15 (25.8%)
Liver HAI 3 16 (27.6%)
>3 42 (72.3%)
Table 2
Results
Viral load at month 6 Median 6118.5 copies/ml
Qualitative PCR 21 (36.2%)
<500,000 copies/ml 49 (84.5%)
>500,000 copies/ml 9 (15.5%)
Viral load at month 12 Median 54243.5 copies/ml
Qualitative PCR 21 (36.2%)
<500,000 copies/ml 48 (82.8%)
>500,000 copies/ml 10 (17.2%)
Virological response Absent 38 (65.5%)
Not sustained 11 (18.9%)
Sustained 10 (17.2%)
Biochemical response Absent 39 (67.2%)
Not sustained 10 (17.2%)
Sustained 9 (15.5%)
Liver Architecture 0-1 40 (69%)
2-3 12 (20.7%)
NA 6 (10.3%)
Liver HAI  3 33 (56.9%)
> 3 19 (32.7%)
NA 6 (10.3%)
NA: Not available
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Tables 3 and 4 show the results of the statistical analysis between
the selected variables and treatment outcome. Univariate analysis revealed
statistical significance only for the basal histological variables, with some
demographic characteristics (female sex and age less than 40 years) being
close to the alpha level of 5%. Logistic regression revealed significance
only for the architectural alterations, with serotype being close to alpha
in relation to the virological response. No significant difference was
observed between any quantitative variable and HCV.
Although these data are not reported, separate statistical analysis
grouping non-sustained and sustained responses (presence of response)
versus lack of response was performed. Univariate analysis showed a
good correlation between virological response and diagnosis by
investigation (p = 0.016) and low viral load after six months of treatment
(p = 0.021).
The fact that some variables were close to alpha indicates that the
sample size was insufficient for confirmation of these data. However,
the trend observed here was comparable to data reported in the literature.
Although the general serotyping sensitivity was good, 13.8% of cases
were lost upon serotype definition and these eight lost cases may have
compromised the analysis.
 DISCUSSION
This study was designed in 1997 in view of the recently published
Hepatitis C Consensus of the NIH22 and carried out during the period
from 1997 to the beginning of 2000. The initial objective was to determine
the role of HCV RNA quantification as a clinical-evolutive and
histological predictor in chronically infected patients treated with
interferon-alpha. During the development of the study and based on the
Table 4
Multivariate analysis/logistic regression
Variable Architectural alteration HAI Virological Biochemical
(after treatment) (after treatment) response response
Sex p = 0.6337 p = 0.0987 p = 0.1094 p = 0.4103
Age p = 0.5848 p = 0.1967 p = 0.5601 p = 0.8542
Serotype p = 0.1048 p = 0.2214 p =0.0714** p = 0.6523
Pre-treatment HAI p = 0.5165 p = 0.1597 p = 0.3838 p = 0.3648
Pre-treatment p = 0.001* p = 0.0494* p = 0.2609 p = 0.2609
architectural OR99.99 OR3.91
alteration (CI 9.31; 1073.51) (CI 1.0037; 15.24)
Basal viremia p = 0.6559 p = 0.6271 p = 0.9018 p = 0.9018
Viremia at 6 months p = 0.7880 p = 0.5600 p = 0.2214 p = 0.2609
Transfusion p = 0.3618 p = 0.8550 p = 0.2815 p = 7503
*Significant; **Close to significance (p = 0.05)
Table 3
Univariate analysis
Variable Architectural alteration HAI Virological Biochemical
(after treatment) (after treatment) response response
Sex p = 1 p = 0.076** p = 0.472 p = 0.703
Age p = 0.473 p = 0.077** p = 0.726 p = 1
Serotype p = 0.489 p = 0.300 p = 0.130 p = 1
Pre-treatment HAI p = 0.023* p = 0.008* p = 0.711 p = 0.243
Pre-treatment p < 0.001* p = 0.025* p = 0.427 p = 0.422
architectural
alteration
Basal viremia p = 0.181 p = 0.242 p = 0.592 p = 0.296
Viremia at 6 months p = 1 p = 1 p = 0.335 p = 0.329
Transfusion p = 0.731 p = 0.798 p = 0.733 p = 1
Diagnosis p = 1 p = 1 p = 0.265 p = 0.218
4
ARAÚJO, E.S.A.; CAVALHEIRO, N.P.; LEITÃO, R.M.C.; TOSTA, R.A.B. & BARONE, A.A. - Hepatitis C viral load does not predict disease outcome: going beyond numbers. Rev. Inst.
Med. trop. S. Paulo, 44(2):71-78, 2002.
results obtained we could define a clear and relevant role of this method
as an evolutive predictor and as a predictor of the therapeutic response
in the population analyzed.
We believe that HCV viral load does not play a predictive role in the
histological evolution of the disease or, at least as observed in the present
study, in the therapeutic response. The initial objective was therefore
reached since we defined interpretative quantification limits and
demonstrated solid and feasible alternatives that would provide
information about the possible course of the disease to both doctors and
patients, i.e., demographic and histological factors.
In Brazil, difficulties exist in performing quantitative or non-
quantitative exams involving molecular biology and the results are
frequently interpreted erroneously based on the assumption that the higher
the HCV viremia the poorer the disease progression. This is based on a
parallelism drawn between HIV and HCV viral load. In fact, HIV viral
load is a reliable predictor of disease progression, while plasma HCV
viremia does not reflect the amount of virus in the liver and the plasma-
liver correlation is not well established29. In addition, technical limitations
still exist for HCV quantification, such as the standardization of the
results between different methodologies, as extensively discussed by
PAWLOTSKY26, and still not completely understood aspects of virus-
host interaction, which make the interpretation of “a high viral load as
an index of severe disease” a naive and incorrect simplification.
So, which role does HCV RNA quantification play and what is its
use? Recent studies on viral dynamics answer this question,
complemented by the understanding of the role of interferon as a
therapeutic agent and its impact on different viral subpopulations within
the context of the host response to HCV. We discuss below different
aspects concerning HCV dynamics and the role of interferon for a better
understanding of our results.
Viral dynamics. The understanding of HCV kinetics is fundamental.
It is known that trillions of virions are produced and eliminated each
day27, remaining in a steady state, an aspect that can be studied using
interferon therapy or plasmapheresis19, procedures that lead to alterations
in the established steady state. Studies on viral dynamics, encouraged
by similar investigations carried out on HIV, have regularly been
conducted since 199539, and the data have been solidified and successively
reproduced in order to better understand HCV pathogenesis and its
response to antiviral therapy. The initial aim was to obtain the optimal
time point to predict a sustained virological response, and 12 weeks
after interferon treatment was established as the best time point to carry
out HCV RNA quantification20. However, quantification during the fourth
week was found to be reliable and able to predict a sustained virological
response2, 4,10. ZEUZEM et al.37 considered undetectability of the virus
during week 4 to be a more important predictor than basal viremia or
genotype. According to LAM et al.17, the early clearance of HCV is due
to the dose-dependent action of interferon. This result was later confirmed
and great emphasis has been placed on viral dynamics since the study
by NEUMANN et al.23 at the end of 1998. These authors showed a
biphasic viral response after the beginning of interferon therapy and
clearly demonstrated a rapid response during the first 24 to 48 h of therapy
accompanied by a marked reduction in viral load. This reduction was
dependent on interferon and related to the inhibition of virion production
and release, being influenced by the efficacy of the drug and directly
dose related. Subsequently, the HCV genotype was also found to be a
determining factor of a better response during this early period18. During
a second slower phase with a variable decrease in viremia, infected cells,
which represent reservoirs for de novo infection, are eliminated. This
second phase is known to depend on the dose and effectiveness of
interferon, on the rate of elimination by infected hepatocytes (ranging
from 1.7 to more than 70 days), on T cell cytokines that inhibit HCV,
and on viral genotype18. A decline in viral load higher than 0.3 log/week
during the first four weeks18 or > 3 log37 is correlated with a sustained
virological response. HCV RNA quantification after 4 weeks of treatment
can therefore be used to predict a response. A sustained virological
response thus results from the efficient action of interferon within a
favorable immunologic scenario that leads to the destruction of infected
hepatocytes18. According to NEUMANN et al.23, interferon exerts
multiple effects, but one vital effect is the blockade of the production or
release of virions during the initial phase of therapy, while other
mechanisms of action may become relevant at other time points during
treatment. However, further studies using combination therapy with
ribavirin and the new peg interferons have become necessary. According
to LAYDEN & LAYDEN18, the effect of ribavirin on viral kinetics is
considerable and the drug does not alter the response curve to interferon,
although further studies employing this combination should be carried
out. Analyzing viral dynamics in patients treated with standard versus
peg interferon, this author emphasized the absence of any modification
in the response curve or between the different drug curves, although
ZEUZEM et al.36 observed superiority of peg interferon for the
elimination rate of genotype 1. Based on the identical results regarding
HCV dynamics obtained by ZEUZEM et al.36, LAYDEN & LAYDEN18
established a paradox: how to explain the superiority of peg interferon
over standard interferon? The author raised the hypothesis that a constant
concentration of interferon stabilizes the inhibition of virus production
and/or increases the degradation of infected cells. In addition, non-1 (2
or 3) genotypes show rapid clearance during phase 2, thus supporting,
from the point of view of viral kinetics, shorter treatment periods for
patients infected with these virus subtypes18.
Irrespective of the type of interferon, the dose or scheme employed,
and viral factors, 30 to 40% of patients treated with interferon show a
triphasic decrease in viral load after the beginning of therapy, with the
curve reaching a plateau at the beginning of the second phase. This fact
can be explained by the initial absence of a significant reduction in viremia,
which, if remaining within the “limit of inhibition” (i.e., 100,000 ± 60,000
IU/ml), is followed by a discontinuation in the decline of viral load (plateau)
which may last 3 to 21 days due to the lack of an efficient immune response.
Once immunity has been restored, viremia starts to fall again3. Therefore,
a triphasic response should be considered before predicting a sustained
virological response based on phase 2 of the response curve. In addition,
phase 1 of the curve determines the presence or absence of this plateau.
Thus, the presence or absence of a sustained virological response can be
predicted as early as within a few hours of therapy. However, further clinical
studies are necessary to thoroughly validate these data, although the initial
argumentation is highly convincing.
Based on the above considerations, we conclude that HCV RNA
quantification plays a role in viral dynamics and can provide an early
prediction (24 to 48 h) of a sustained virological response. On the other
hand, disease progression is more complex and does not simply depend
on viremia.
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The role of interferon. Interferon-alpha acts in two distinct and
complementary manners. On the one hand, it induces a nonspecific
antiviral state in the infected cell, thus impairing HCV replication, and
on the other it exerts an immunomodulatory action that potentiates the
host immune response25. These actions are induced by binding to target
cell surface receptors, triggering a cascade of intracellular reactions that
lead to the activation of numerous genes whose products mediate the
action of interferon. Although several interferon-induced proteins are
involved, only three have been extensively studied: 2’-5’ oligoadenylate
synthethase (2’5’OAS), Mx proteins (MxA and MxB), and double-strand
RNA-dependent protein kinase (PKR). The Mx proteins seem to be less
important for HCV (25), while 2’5’OAS and PKR, nonspecifically
activated by virus replication products (RNA), are fundamental. Both
proteins interfere with the synthesis of new virus particles - 2’5’OAS
through endoribonucleases (Rnase L) that destroy virus precursors and
PKR by inactivating the eukaryotic initiation translation factor eIF2,
thus blocking virus replication.
The immunomodulatory action of interferon-alpha occurs after
binding to receptors on the surface of immune cells, triggering four main
actions: induction of antigen expression through MHC I, activation of
effector cells (natural killer cells, macrophages, cytotoxic T lymphocytes),
interaction with the cytokine cascade stimulating the production of T
helper cells (Th1) (producing INF- and IL-2) and reducing Th2 cells
(main producers of IL-4 and IL-5), and anti-inflammatory actions
inhibiting the production of IL-1, IL-8 and TNF- and stimulating the
production of IL-10 at the periphery.
Based on the lack of a completely efficient therapy and the fact that
the results in terms of virus eradication are in fact quite unsatisfactory, it
is important to evaluate and understand which mechanisms of interferon
resistance are used by HCV. An outstanding line of research during recent
years was initiated by ENOMOTO et al.8, who described a region
associated with the response to interferon - called interferon sensitivity
determining region (ISDR) - located between amino acids 2209 and
2248 of the NS5A protein in an HCV 1b strain, called HCV-J. Strain
HCV-J was considered to be the wild type, with mutations (4 to 11 amino
acid substitutions) being related to a higher probability of therapeutic
response, a fact that defines the presence of an ISDR mutant as a predictive
factor for response.
The lack of reproducibility of these data outside Japan and
inconsistent in vivo results aroused some initial suspicion and even irony
(could this be a “Japanese effect”?)13. In fact, most European researchers
did not find the same relevance of ISDR mutations as predictors of
response16,32,38, except for one study12. In this regard, data were
reproduced21 and refined, demonstrating that the larger the number of
mutations, the stronger the correlation with a sustained virological
response, especially when the mutations occurred in amino acids 2209,
2216 and 2227. In addition, the relevance of ISDR found in the Japanese
study was categorically reaffirmed, irrespective of the discrepancies from
western studies35.
The differences in the data between Japan and the western world
were subsequently investigated more extensively and meta-analysis of
the available studies revealed that the ISDR is only valid as a predictor
for genotypes 1a and 1b24, with three possibilities being proposed to
explain the conflicting results: ISDR is not the only region of the NS5A
gene involved in the inhibition of the antiviral effects of interferon, other
factors (e.g., race) may have interfered with the European studies, and
an undetectable number of ISDR resistant quasispecies are present before
treatment which eventually predominate during therapy24.
Despite the controversy, the mechanism of interference of ISDR with
the response to interferon was unknown until GALE Jr. et al.9
demonstrated an interaction between the carboxy terminal portion of
NS5A and PKR. The interferon-induced PKR gene possesses multiple
functions activated by double-strand RNA, including pro-apoptotic
actions, growth control and differentiation and, obviously, the previously
discussed inhibition of translation in response to viral infection9.
Interaction between PKR and NS5A inhibits the functions of this kinase,
while an ISDR mutant loses this binding capacity and therefore maintains
the effects of the PKR kinase.
Based on the fact that the ISDR studies on European patients were
conducted after treatment, PATERSON et al.24 performed an in vivo
analysis of the NS5A region in western patients using samples collected
before and during treatment and using different genotypes. The following
observations were made: genotype 1 possessed the same behavior as the
HCV-J strain; no differences in the NS5A region were observed between
non-1 genotypes and HCV-J, while the criteria for ISDR mutation were
noted (these being therefore “sensitive” genotypes); the ISDR of genotype
3 differed from that of genotype 4, with genotype 3 being responsive
and 4 being non-responsive; a higher amino acid diversity was observed
for genotype 1 compared to non-1; genotype 1 showed higher ISDR
diversity before treatment, with interferon exerting selective pressure
and reducing diversity during treatment; alterations in more than three
ISDR amino acids predicted a response for genotype 3 but not for
genotype 4, and, finally, a specific model is required to understand the
NS5A/PKR interaction in the case of non-1 genotypes, since the model
of Enomoto was found to be inadequate. These observations led to the
following two conclusions. First, no resistant quasispecies occurred
during treatment, thus excluding an explanation for the differences
observed between Japan and the western world, and, second, the ISDR
should not be considered as the only response determining factor among
European patients. In fact, mutations in a region comprising amino acids
2356 to 2379 of the NS5A gene, called V3, are correlated with an
interferon response through an as yet unknown mechanism33.
Recently, PODEVIN et al.28 have extended the discussion about the
role of NS5A, questioning previous models that did not analyze the role
of NS5A in hepatocytes and whose results should therefore be considered
with caution. In their study, the first one on hepatocytes, the authors
analyzed human hepatocytic cell lines (Huh 7) expressing NS5A
sequences derived from one responder and two non-responders in the
presence of interferon-alpha and exposed to virus strains sensitive to the
drug. When the antiviral action of interferon was measured, NS5A was
found to confer resistance. The ISDR of the responder corresponded to
the interferon-sensitive virus, while a non-responder represented the wild
type and the other possessed 8 amino acid mutations. Exposure to
interferon resulted in virus multiplication in the wild type (ISDR resistant)
but, surprisingly, also in the mutants (ISDR sensitive), although to a
lesser extent. Thus, NS5A plays an ISDR-independent role in the escape
from interferon, since mutations in this region are not associated with
treatment efficacy. The authors therefore concluded that neither the
mutant nor the wild type depend on PKR and proposed NS5A-induced
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IL-8 expression as a possible mechanism for the inhibition of the antiviral
actions of interferon.
According to PODEVIN et al.28, NS5A participates in at least four
actions:
1. It interferes with the double-strand RNA-dependent interferon-
induced PKR kinase.
2. NS5A-mediated PKR inhibition may abolish PKR-dependent
apoptosis (a fundamental process for the destruction of infected
hepatocytes which occurs during the second phase of the viremia
reduction curve in response to interferon, as emphasized by
WATANABE et al.35 who showed that apoptosis is also induced by
TNF-alpha which in turn is mediated by interferon-alpha) and induce
phenotype alterations in NIH3T3 cells (carcinogenesis?).
3. Cis transactivation of various elements such as Grb2 - abolished in
mutant strains.
4. NS5A may interfere with nuclear RNA and protein transport by
interacting with karyophenin ß3.
Therefore, NS5A expression may play a crucial role in the control
of the antiviral and proliferative state of HCV-infected hepatocytes
through interaction with multiple cell signaling pathways. This protein
should be thoroughly studied in other models since it contains domains
(ISDR, PKR-binding domain, V3) that are fundamental for the
understanding of the interaction with interferon. TAYLOR33 observed
that in all models available NS5A inhibited the action of interferon
regardless of sequence or genotype. The author thus proposed that a
basal level of NS5A expression confers some protection on the virus,
opening the possibility that other viral genes or host factors determine
resistance to interferon, for example, the highly conserved sequences of
the E2 region of interferon-resistant genotypes which act by inhibiting
PKR. Therefore, E2 may confer a basal level of resistance on resistant
genotypes and new therapies should consider the neutralization of this
basal inhibition of endogenous or exogenous interferon which is certainly
mediated by genes other than NS5A and E2.
PAWLOTSKY25 divided resistance-related factors into factors
associated with treatment, patient, disease and viral factors, as follows:
Treatment-related factors:
1. Treatment scheme during induction: three times a week is inadequate
in terms of viral kinetics since viremia increases before the second
dose (this effect is reduced by ribavirin and daily interferon doses or
peg interferon).
2. Treatment duration: a longer duration is associated with fewer
relapses.
Patient-related factors:
1. Age (the older the patient the poorer the response)
2. Sex (females show a better response)
3. Race (Hispanics and Africans show a poorer response than
Caucasians and Asians) - the first three races show genetic, hormonal
and/or immunological determinants.
4. Weight (alters drug distribution, reducing its concentration in the
receptors).
5. Anti-interferon antibodies.
6. Habits: alcoholism, drug use.
7. Treatment compliance.
Factors related to disease and associated with a poor response:
1. Advanced fibrosis and compensated cirrhosis.
2. HIV-HCV co-infection
3. Extra-hepatic manifestations.
4. Non-response to previous treatments.
5. Normal ALT and poorly active chronic hepatitis (which are in fact
“patients for whom it is difficult to decide about a therapy” rather
than patients “difficult to treat”).
HCV-associated factors:
1. Diverse and numerous populations of quasispecies: absence of
intrinsic resistance since at a certain time viremia is always reduced
in response to interferon. The modifications result from the adaptation
of these populations to the environment created in the presence of
interferon, bearing in mind that interferon does not act directly on
HCV but stimulates an unfavorable environment for the virus.
Therefore, no resistance to the drug but rather adaptation to the hostile
environment exists, in contrast to the previously discussed proposal
of TAYLOR33 with respect to the basal protection level conferred by
NS5A and E2, among other probable factors.
2. Genotypes. Probably related to differences in nucleotides which result
in different proteins among isolates, with a greater or lower capacity
to escape the actions of interferon. Again, a role for NS5A, E2 and
even viral polyprotein is proposed, which may inhibit the Jak-Stat
pathway, the main interferon signal transduction pathway.
Based on this vast panorama and the absence of new clarifying
experiments confirming in vivo results, PAWLOTSKY25 reached three
conclusions regarding interferon resistance: i) resistance to interferon is
multifactorial, ii) is characterized by significant qualitative and
quantitative population alterations, and iii) such alterations can have
consequences for the prognosis of hepatic disease.
One aspect that should be considered at the end of this discussion is
the fact that patients with advanced fibrosis due to hepatic cirrhosis show
an unfavorable disease course. In view of the difficulties in eradicating
HCV, various reports have emphasized the importance of interferon as a
modulating agent of fibrogenesis in non-responders, such as the recent
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study by ALRIC et al.1. Furthermore, some studies have reported
complete resolution of hepatic cirrhosis5. WANLESS34 partially agreed
with this study by emphasizing that vascular lesions remained despite
the removal of collagen. However, clinical studies have demonstrated
the effective modulation of fibrogenesis. SIME & O’REILLY31 postulated
the hypothesis that fibrosis is the result of a disequilibrium in the Th1/
Th2 immune response, with the type 1 response being associated with
tissue architecture restoration and type 2 with exuberant fibroblast
activation and proliferation, thus causing fibrogenesis. Interferon- -
the prototype of the Th1 response - possesses various potential actions
on fibrogenesis (i.e., inhibition of fibroblast proliferation and collagen
deposition, promoting apoptosis of fibroblasts and inhibiting TGF-, a
fibrogenic cytokine) and its action is increased by other type 1 cytokines.
Experimental and animal models have confirmed this hypothesis, thus
opening a field for the study of treatments of diseases that result in tissue
fibrosis31. As mentioned before, interferon-alpha favors a Th1 response,
an effect that might modulate fibrogenesis in the models proposed by
SIME & O’REILLY31.
Based on a study in which the nowadays inadequate interferon
monotherapy was used, our results and the review of the literature
demonstrated that hepatitis C evolution depends on multiple factors
related to histological, host and viral aspects, including not only
quantitative factors but mainly the diversity and dynamics of the viral
population, in addition to aspects of treatment. We were able to
demonstrate that viremia is an important aspect but should not be used
alone for the prediction of disease outcome since its interpretation differs
from that of HIV viremia. Although our study design might be criticized
and considered to be old-fashioned due to the use of monotherapy, our
model was found to be strong and sufficient to suggest what subsequent
investigations confirmed - such as the recent study by GERVAIS et al.11
who demonstrated in a similar study that viremia is correlated with
genotype and response to treatment but not with histological lesions -
and to broaden the set of possibilities to study and better understand the
different aspects of hepatitis C. In this respect, the professionals involved
with hepatitis C should have an ample vision and should be aware of the
extreme velocity at which knowledge about the pathogenesis of the
disease and implications for patient follow-up and treatment accumulate.
RESUMO
A carga viral do vírus da hepatite C não prediz a evolução: indo
além dos números
Através da análise de 58 pacientes tratados com Interferon Alfa em
função de hepatite C crônica e sem cirrose, demonstramos que a carga
viral do Vírus da Hepatite C (VHC) não se correlacionou com a evolução
histológica da doença (p = 0,6559 para alterações arquiteturais e p =
0,6271 para o Índice de Atividade Histológica-IAH). Assim a utilização
da quantificação do RNA viral como preditor evolutivo ou determinante
da gravidade da hepatite C é incorreto e de valor relativo. Revisando o
tema encontramos variáveis do VHC (genótipo, heterogeneidade e
mutantes, proteínas específicas), do hospedeiro (sexo, idade, peso, etc)
e dos medicamentos (posologia, tempo de tratamento, tipo de Interferon)
fundamentais e interdependentes, inseridas no contexto mais amplo da
cinética viral, da resposta imunológica mediada pelo Interferon (além
da imunidade natural em resposta ao VHC) e do papel do Interferon
como modulador da fibrogênese. Assim, há muito mais que números
por trás da Carga Viral e sua correta interpretação deve ser feita
considerando-se um horizonte mais amplo dependente de múltiplos
fatores mais complexos que o simples valor obtido na quantificação
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